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GITR/TNFRSF18 is a member of the TNF-receptor
superfamily preferentially expressed on regulatory T
cells (Tregs) and activated T effector cells. Antibody
agonists to GITR claim two distinct mechanisms to
overcome the repressive tumor microenvironment and
drive anti-tumor efficacy in vivo: receptor agonism (for-
ward signaling) on T effector cells and FcgR-mediated
Treg depletion. We sought to better understand the
contribution of these two mechanisms using pharmaco-
dynamic readouts relating target coverage, Treg deple-
tion and efficacy using isotypic variants of a surrogate
antibody against mouse GITR, DTA-1.
First, target coverage was determined in spleen, tumor
and draining lymph node following treatment with a
single dose of mouse IgG2a DTA-1. In this study, effi-
cacy correlated with doses that covered >90% GITR-
expressing intratumoral leukocytes and depleted >90%
intratumoral Tregs at 24 hours post-dose. Though dis-
playing equivalent agonistic activity in vitro and achiev-
ing a similar level of target coverage, the mouse IgG1
N297A variant of DTA-1 neither depleted Tregs nor
displayed anti-tumor activity in vivo, in confirmation of
recent literature. To further explore the influence of Fc
engagement, additional DTA-1 isotypic variants were
generated and tested in vivo. In this study, we confirmed
that preferential engagement of Fcg receptors was neces-
sary for optimal activity, as the mouse IgG1 DTA-1 var-
iant failed to regress tumors. Additionally, we identified
a variant with enhanced Treg depletion properties, how-
ever, the enhanced depletion did not translate to
improved anti-tumor efficacy.
Lastly, we sought to understand if mouse IgG2a DTA-
1-would enhance the effect of PD-1 / PD-L1 blockade
in vivo. Using the MC38 tumor model, we observed
synergistic tumor regression in the combination group
versus either monotherapy. Given the likely non-over-
lapping mechanism of the antibodies, the results suggest
that an ADCC-enabled agonistic GITR antibody could
provide benefit to human cancer patients in combina-
tion with, or refractory to, PD-1/PD-L1 inhibitors
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